Meenu Chhabra Karson
President & Chief Executive Officer
Ms. Chhabra Karson has been Allozyne’s President and Chief Executive Officer since September 2007 and Allozyne’s director since October 2007. Prior to Allozyne, she served as Vice President of Business Development and Licensing for Novartis (Switzerland) from November 2006 to August 2007. While at Novartis, she specialized in leading and executing merger and acquisition transactions in emerging markets. Before joining Novartis, she served as Chief Business Officer at BioXell SpA, a spin-off from F. Hoffmann-LaRoche Ltd.’s Milan Research Institute (Italy) from September 2003 to October 2006, where she led corporate development and financing activities, which culminated in a series of transactions with top-tier pharmaceutical companies including Merck & Co., Inc., and F. Hoffman-LaRoche Ltd. Ms. Chhabra Karson has also held management positions with Fresenius Kabi AG, Warner Lambert, Inc., and Bristol-Myers Squibb, Inc. She obtained her M.B.A. from York University and her B.Sc. from the University of Toronto. Ms. Chhabra Karson brings to the board a deep familiarity with Allozyne’s operations, strategy and vision and a strong record of successful corporate and product portfolio planning and management.
Kenneth Grabstein, Ph.D.
Chief Scientific Officer
Dr. Grabstein has been Allozyne’s Chief Scientific Officer since October 2005. Prior to Allozyne, Dr. Grabstein was at Immunex Inc., where he spent 12 years in R&D leading the discovery and characterization of cytokines and other protein immuno-modulators. He went on to co-found Corixa Corporation, a biotechnology company that was acquired by GlaxoSmithKline plc in July 2005 and led a research team of 100 scientists engaged in the discovery and development of immuno-therapeutics. He has published over 100 articles in peer-reviewed scientific journals and is an inventor on over 20 issued patents. Dr. Grabstein holds Affiliate Faculty positions at the University of Washington and Roswell Park Cancer Institute. Dr. Grabstein received his Ph.D. in Immunology from the University of California, Berkeley, in 1982. Dr. Grabstein brings to the board an in-depth understanding of the science and clinical history of Allozyne’s product candidates.